This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Blarcamesine
- DrugBank Accession Number
- DB05592
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Blarcamesine (DB05592)
- Weight
- Average: 281.399
Monoisotopic: 281.177964365 - Chemical Formula
- C19H23NO
- Synonyms
- Anavex 2-73
- Blarcamesine
- Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanemethanamine
- THD-DP-FM
- External IDs
- AE-37
- AE37
- ANAVEX 2-73 FREE BASE
Pharmacology
- Indication
Investigated for use/treatment in breast cancer.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 9T210MMZ3F
- CAS number
- 195615-83-9
- InChI Key
- BOTHKNZTGGXFEQ-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H23NO/c1-20(2)15-18-13-14-21-19(18,16-9-5-3-6-10-16)17-11-7-4-8-12-17/h3-12,18H,13-15H2,1-2H3
- IUPAC Name
- [(2,2-diphenyloxolan-3-yl)methyl]dimethylamine
- SMILES
- CN(C)CC1CCOC1(C1=CC=CC=C1)C1=CC=CC=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 8057864
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Parkinsons Disease With Dementia (PDD) 1 2, 3 Active Not Recruiting Treatment Rett Syndrome 1 2, 3 Recruiting Treatment Alzheimer's Disease (AD) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0197 mg/mL ALOGPS logP 3.73 ALOGPS logP 3.5 Chemaxon logS -4.2 ALOGPS pKa (Strongest Basic) 9.54 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 12.47 Å2 Chemaxon Rotatable Bond Count 4 Chemaxon Refractivity 87.57 m3·mol-1 Chemaxon Polarizability 32.57 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Drug created at November 18, 2007 18:26 / Updated at February 21, 2021 18:51